914347-52-7 Usage
Uses
Used in Pharmaceutical Industry:
2-AMINO-5-BROMO-4-DIMETHOXYMETHYLPYRIMIDINE is used as a chemical intermediate for the development of new drugs due to its unique structural features and potential biological activities. Its presence in drug formulations can contribute to the modulation of various biological pathways, thereby enhancing therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 2-AMINO-5-BROMO-4-DIMETHOXYMETHYLPYRIMIDINE is utilized as a precursor in the synthesis of pesticides. Its chemical properties allow for the creation of compounds that can effectively target and control pests, thereby increasing crop yields and ensuring agricultural productivity.
The specific applications and reasons for using 2-AMINO-5-BROMO-4-DIMETHOXYMETHYLPYRIMIDINE in these industries highlight its versatility and importance in the development of innovative products that address current challenges in health and agriculture.
Check Digit Verification of cas no
The CAS Registry Mumber 914347-52-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,4,3,4 and 7 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 914347-52:
(8*9)+(7*1)+(6*4)+(5*3)+(4*4)+(3*7)+(2*5)+(1*2)=167
167 % 10 = 7
So 914347-52-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H10BrN3O2/c1-12-6(13-2)5-4(8)3-10-7(9)11-5/h3,6H,1-2H3,(H2,9,10,11)
914347-52-7Relevant academic research and scientific papers
Borsari, Chiara,Rageot, Denise,Dall'Asen, Alix,Bohnacker, Thomas,Melone, Anna,Sele, Alexander M.,Jackson, Eileen,Langlois, Jean-Baptiste,Beaufils, Florent,Hebeisen, Paul,Fabbro, Doriano,Hillmann, Petra,Wymann, Matthias P.
, p. 8609 - 8630 (2019)
The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure-activity relationship (SAR) studies led to the identification of compound 12b with a ～450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.
